Moreover, a previous patent has demonstrated that the KHDRBS2 serves as a biomarker for the prognosis of GBM, and methylation status of KHDRBS2 correlates with the clinical survival outcome of GBM patients [36]. The gene discussed is KHDRBS2; the disease is glioblastoma.